Abstract: Cancer immunotherapy for urological tumors had made progress for several decades, but recent advances in immunotherapy, as therapeutic vaccines or immune checkpoint inhibitors, have drastically changed the present treatment strategy. Recently, nivolumab and atezolizumab have been approved by the Food and Drug Administration for treatment of urological cancers. Additional immune checkpoint inhibitors and vaccines are being tested in clinical trials. Despite advances in these therapeutic modalities, benefits are limited to a subset of patients. New agents and novel combinations will also continue to create new immunotherapy strategies. Further development of biomarkers for predicting response is required to achieve optimal efficacy with these therapeutic interventions.
Introduction
Although immunotherapy for urological cancers is not a new treatment, 1 recent basic and clinical advances have confirmed the value of immunotherapy as a urological cancer treatment. The use of therapeutic cancer vaccines for prostate cancer and of ICIs for RCC and UC is providing evidence that immune-based treatments can drastically improve survival or antitumor effects for patients with advanced urological cancers. However, because only certain patients obtain this benefit as a durable response, we need to identify predictive biomarkers. In the present review, we discuss basic cancer immunotherapy, recent clinical trials of immunotherapy for urological cancers and potential new directions for these therapies, including new agents, combinations and predictive biomarkers.
Basic immunological mechanism
Immunotherapy is defined as excluding cancer by generating or activating an autoimmune response against the tumor rather than by attacking the tumor directly. The immune system is important in cancer cell surveillance and elimination, and immune evasion of cancer cell populations by various mechanisms is considered one of the hallmarks of cancer. 2, 3 T-cell development and activation is regulated by various stimulatory and inhibitory signals, which protect normal cells. Tumors have discovered how to use this protective mechanism to evade the immune system. Chen and Mellman have described the cancer immunity cycle in detail. 4 The adaptive immune response requires presentation and education about its targets. The turnover of cancer cells and associated cell death leads to the release of tumor-associated antigens, which are typically overexpressed or mutated proteins that are then captured by antigen-presenting cells, the dendritic cells. These cells migrate to lymphoid organs, whereas effector T cells are being educated and activated, which in turn will traffic throughout the host, infiltrate tumors, and recognize and kill cancer cells expressing specific tumor-associated antigens or mutated proteins. They do so by recognizing respective peptides that are presented through the MHC I to the TCR. This leads to further activation and expansion of reactive T-cell clones, which engage their targets by releasing an arsenal of cytotoxic molecules, such as granzyme and perforin. This process can release further antigens, which in the best scenario leads to detection of several tumor-specific epitopes ("epitope spreading"), broadening of the immune response and potential exclusion of the tumor cells.
Immune checkpoints
Regulatory mechanisms exist at each point of the immunity cycle that can weaken or suppress the immune response to protect from an excessive autoimmune response. These breaks in the immune system are often referred to as "immune checkpoints" that can be usurped by the tumor and its associated microenvironment to protect the tumor from an effective immune response. Interestingly, the recent revolution in immuno-oncology has been primarily achieved by targeting and releasing the breaks in the immune system.
The immune system recognizes cancer cells as foreign entities. The MHC presents foreign antigens as well as selfantigens. T cells distinguish between cells that the immune system should attack and those that should not depend on the presence of costimulatory or inhibitory proteins. When the CD28 protein on T cells binds to CD80 or CD86 (called B7-1 and B7-2) in the presence of a TCR-MHC interaction, the T cell is stimulated. Alternatively, when CTLA-4 binds to CD80/CD86, T cells are inhibited. In addition to the CTLA-4 checkpoint, the PD-1 protein is also expressed on T cells, and when it binds to its ligand (PD-L1) on the surface of antigen-presenting cells or tumor cells, that too suppresses Tcell activity (Fig. 1) . 5 Tumor genetic instability results in mutant proteins, which in turn result in the production of abnormal antigens called neoantigens. The presence of these neoantigens in combination with certain features of the tumor microenvironment probably allows the immune system to attack and destroy tumor cells. [6] [7] [8] Tumor cells can regulate the immune checkpoint pathways to avoid being eliminated by the immune system. Therefore, blocking immune checkpoints, such as the CTLA-4 and/or PD-1/PD-L1 pathway, might restore the antitumor activity of T cells.
Prostate cancer
The FDA approved therapeutic vaccines (sipleucel-T) for prostate cancer in 2010. This agent is designed to work at least in part by generating or augmenting an antitumor immune response. Sipleucel-T, an autologous cellular therapy, showed an OS benefit of 4.1 months in patients with asymptomatic or minimally symptomatic CRPC (25.8 months vs 21.7 months for placebo). 9 Recently, a subsequent analysis suggested that patients in the placebo group who were later given cryopreserved immune cells as part of a planned crossover might have performed better clinically than would have been expected. 10 Therefore, the results of the phase III study might have underestimated the actual therapeutic benefit. Another therapeutic cancer vaccine in development is PSA-TRICOM (PROSTVAC), a poxviral-based vaccine targeting PSA that has shown an OS advantage in a randomized phase II study and completed accrual to a phase III trial, with results expected by early 2017. 11 It is, therefore, probable that vaccine therapy will have a growing role in the treatment of prostate cancer.
Another approach is a personalized peptide vaccine, which uses multiple tumor-associated antigens based on the preexisting host immunity. In Japan, two phase II studies have been carried out in patients with post-docetaxel, 12 with one showing a longer OS time. 13 Another phase II study showed a delay in progression-free survival of PSA in patients with chemotherapy-na€ ıve CRPC. 14 The researchers suggested that early-stage CRPC with a performance status of 0 or 1 and PSA <10 ng/mL might receive preferable clinical benefits from peptide vaccine treatment. A randomized phase III study is now progressing for patients with early-stage CRPC.
ICIs have also been investigated for CRPC, but little efficacy has been shown. Ipilimumab (anti-CTLA-4) has been examined in phase I, II and III trials, as a monotherapy, and in combination with hormonal-, cytotoxic-and radiotherapies. Ipilimumab 10 mg/kg, in combination with radiation (bonedirected palliative radiation; XRT; single dose of 8 Gy), in a post-docetaxel setting of a phase III trial showed few durable responses, and did not show a significant difference in OS (11.2 months for ipilimumab vs 10.0 months in placebo; HR 0.85, 95% CI 0.72-1.00; P = 0.053). 15, 16 However, crossover of the Kaplan-Meier curve was noted at 7-8 months, and on further analysis, the proportional hazard assumption was violated. Modeling showed that the HR decreased over time; after 12 months, the HR was 0.60 (95% CI 0.43-0.86), which suggested a prolonged effect from ipilimumab therapy. Also of interest, post-hoc analysis showed a possible benefit in patients with pretreatment alkaline phosphatase <1.5-fold the upper limit of normal, hemoglobin >11 g/dL, and no visceral metastasis. Updated OS results at 3 years showed maintained results, as in the primary analysis, as well as a 3-year OS of 12% in the ipilimumab versus 6% in the placebo. 17 Although the primary end-point was not met in this phase III trial, questions remain regarding the choice of ipilimumab, XRT dose and sequence therapy, as well as the inclusion of patients with visceral metastatic disease and prior chemotherapy. A second phase III trial of ipilimumab versus placebo in patients with minimal or asymptomatic CRPC has been completed, but results are not available yet (NCT01057810). The ongoing clinical trials regarding ICIs for prostate cancer are listed in Table 1 .
Recent studies have suggested limited antitumor immune infiltrates in prostate cancer with minimal associated PD-L1 expression. 18 These observations might explain the lack of ORRs seen to date with agents targeting PD-1 or PD-L1 in prostate cancer. 19 As demonstrated by select patients showing responses in many of these studies, it might be possible that immunotherapy for prostate cancer needs to be more patient selective. Along with target-specific markers, selecting patients with higher mutational load might select for patients who are more likely to respond to immunotherapy. 6, 20, 21 Recent studies have shown that CRPC patients vary widely in mutational burden and mutational spectrum. Mismatch repair deficiency might allow for increased burden of somatic mutations, leading to the generation of tumor-associated antigens that are then targeted by a checkpoint inhibitor-generated immune response. 22 It has also been shown that a subgroup of CRPC patients have alterations in DNA-repair proteins. 23 An analysis of prostate tumors has shown that ≤22% of tested samples had mutations in DNA repair/recombination genes, including MSH2 and MSH6, which suggested that mismatch repair could play a role in the response to checkpoint inhibition in CRPC.
Urothelial cancer
In patients with mUC, the median survival time with standard cisplatin-based chemotherapy is approximately 14 months. 24 Prognosis is extremely poor, with responses to second-line single-agent chemotherapy in the range of 10-20% after firstline chemotherapy. 25 Only vinflunine treatment has been approved in some European countries as a second-line treatment until recently. 26 There is significant evidence that immune oncological therapies would work in metastatic urothelial carcinoma or muscle-invasive urothelial cancer. Muscle-invasive urothelial cancer is known to have a high amount of regulatory T cells in the tumor and in circulation. 27 In muscle-invasive urothelial cancer, increased CD8 + cells infiltrating the tumor have been correlated with longer progression-free survival and OS. 28 We have reported two novel tumor-associated-antigens through expression profile analysis of bladder cancers. 29, 30 HLA-A*24:02-restricted epitope peptides from these antigens have been shown to induce strong CTLs, which were able to kill tumor cells expressing these antigens in a HLA-restricted manner. 31 We also carried out a phase I/II study using these peptide vaccines in advanced UC patients who were resistant to cisplatin-based chemotherapy, and showed that this therapy was well tolerated and effectively induced peptide-specific CTLs, which were correlated with longer survival for patients. 32 PD-1/PD-L1 checkpoint inhibitors have dramatically changed the treatment strategy for mUC. A phase I study of the anti PD-L1 antibody, atezolizumab, in platinum-resistant patients was carried out. Patients were stratified by expression of PD-L1 in lymphocytes found in the tumors based on immunohistochemistry. 33 Approximately 25% of patients showed an ORR, and 43.3% had PD-L1 immunohistochemistry scores of ≥2 or ≥3. In patients with ≥1 or no PD-L1 expression, the ORR was 11.4%. This treatment was well tolerated, with 4.4% of patients having grade ≥3 adverse events. A phase II study follow-up study enrolled 316 patients with mUC who had progressed on platinum-based chemotherapy (IMvigor 210 cohort 2 [NCT02108652]). A total of 64% of patients experienced a reduction in target legions from baseline. Patients with highly or moderately expressed PD-L1 on TILs had a 26% ORR, and those with low or no expression of PD-L1 on TILs had a 10% ORR. 34 OS was 7.9 months, with a 12-month OS rate of 36%, which was significantly higher than the historical rate of 20% for standard chemotherapy. After 17.5 months of follow up, approximately 71% of the responses were ongoing. 35 Most responses were rapid, with a median time to response of 2.1 months. Based on these trials, FDA approved atezolizumab in May 2016 for the treatment of metastatic UC progressing after platinum-based chemotherapy. A phase III study comparing atezolizumab with chemotherapy in this patient population is ongoing (NCT02302807). PD-L1 is expressed in all stages of UC, with approximately 40% of patients having PD-L1 expression on TILs. 36 The efficacy of ICIs appears to be associated with the number of pre-existing CD8 + T cells, which might also upregulate PD-L1 expression in cancer and/or immune cells, 33 and highlights the importance of CTL tumor infiltration as a predictor of treatment efficacy.
A significant proportion of patients with locally advanced/ metastatic UC is not eligible for cisplatin-based chemotherapy because of poor performance status or impaired renal function. Carboplatin-based chemotherapies are commonly used in this setting, but have low ORRs, short duration of response and no evidence of improvement in OS. Cohort 1 of the IMvigor 210 study treated 119 cisplatin-ineligible patients with atezolizumab in the first-line setting. 35 ORR was 24%, with a 7% CR. Interestingly, PD-L1 expression on TIL had little to no effect on ORR (range 21-28%), CR rate (range 6-8%) or OS (range 12.3-15.3 months). The median time to response was 2.1 months, and 75% of the responses were durable at 14.4 months of follow up. The estimated OS was 14.8 months, and the 12-month OS was 57%.
Pembrolizumab (anti PD-1) and avelumab (anti-PD-L1) have also been investigated. An ongoing phase III trial of pembrolizumab versus chemotherapy in previously treated mUC has completed accrual, with the readout coming soon. Adverse events were seen at a slightly lower rate for avelumab, which led to a phase III study trial of maintenance avelumab versus supportive care alone (NCT02603432). Avelumab has recently received the FDA breakthrough designation on the basis of the results seen in the phase I study.
This designation has led to multiple ongoing studies with PD-1/PD-L1-targeting agents alone or in combination with other agents in various stages of urothelial cancer. 37, 38 The ongoing clinical trials regarding ICIs for bladder cancer are listed in Table 2 .
Although ICIs in mUC have generated great excitement, more needs to be done to identify patients who will respond. UC has one of the highest mutational rates of all cancers; however, those rates vary greatly among patients. [39] [40] [41] Rosenberg carried out a deep dive into the phase II atezolizumab trial, and showed that patients with positive PD-L1 TILs, high mutational load and increased expression of CXCL9/ CXCL10 were associated with response, and combining these three factors increased the prediction rate of benefit. There is also evidence that higher tumor T-cell infiltration, clonal T cells within the tumor and circulating antitumor T cells are associated with increased response to atezolizumab. 42 
Renal cell carcinoma
RCC is an immunologically sensitive tumor. Cytokine therapy, as IFN-a and interleukin-2, was the main treatment of metastatic RCC until approval of molecular-targeted medicines. IFN-a2b given subcutaneously had ORRs that ranged from 7% to 14% in studies comparing IFN with medroxyprogesterone acetate in which IFN showed an OS benefit (HR 0.72). [43] [44] [45] High-dose interleukin-2 has ORRs of 15-28%, with CR rates in the 3-7% range. [46] [47] [48] Some of these responses were durable and continued for a long time. Although high-dose interleukin-2 has become the preferred treatment, this treatment is inpatient only and must be given at a center of expertise because of severe toxicity. 35 Given the possibility of durable, long-term responses, high-dose interleukin-2 is an appropriate initial treatment for healthy patients.
Vaccine treatment also has been attempted for RCC. IMA901 is a therapeutic vaccine consisting of nine different HLA class I (i.e. HLA-A*02)-binding tumor-associated peptides and one HLA class II-binding tumor-associated peptide. Recently, a phase III open-label trial in mRCC patients that used IMA901 vaccine was reported. 49 As a first-line setting after one cycle of sunitinib, patients were randomized 3:2 for up to 10 intradermal vaccinations of IMA901, a peptide vaccine, plus 75 lg GM-CSF plus sunitinib versus sunitinib alone. Patients in the vaccination arm were given a single infusion of cyclophosphamide 3 days before the first vaccination to reduce regulatory T cells. Unfortunately, the median OS did not differ significantly between the groups (33.17 months in the sunitinib plus IMA901 group vs not reached in the sunitinib monotherapy group; P = 0.087). Another phase III vaccination trial with AGS-003, an autologous tumor RNA-pulsed dendritic cell vaccine, is eagerly awaited (NAC01582672). This trial randomized patients with cytoreductive nephrectomy who received either sunitinib alone or in combination with the dendritic vaccine, AGS-003. In the future, vaccination approaches will probably be further tailored to the patient's mutanome and tumor-associated antigen profile, with the goal of individualizing treatments and, thus, maximizing the potential benefits. [50] [51] [52] Nivolumab (anti-PD-1) showed an OS benefit in patients previously treated with tyrosine kinase inhibitors for mRCC, which led to FDA approval. 19, [53] [54] [55] A phase III study, CheckMate 025, randomized advanced RCC patients who had one or two prior tyrosine kinase inhibitors to treatment with nivolumab (n = 410) or everolimus (n = 411). Although progression-free survival was similar between the groups, the primary end-point of OS favored nivolumab over everolimus (25 months vs 19.6 months; HR 0.73; P = 0.002). In addition, the ORRs were 25% versus 5% (HR 5.98; P < 0.001). Approximately 35% of patients were still alive after 4-5 years of follow up in phase I and II studies. Expression of PD-L1 did not correlate with improved OS. Nivolumab was also very well tolerated, and a lower proportion of patients developed grade ≥3 toxicities (19% vs 37%). In fact, quality of life scores improved for patients treated with nivolumab, and were superior to the treatment with everolimus.
Other PD-1 and PD-L1 antibodies (pembrolizumab and atezolizumab) have been investigated in this same setting. Preliminary results assessing atezolizumab in mRCC showed an 18% ORR with increased RR in patients with increased PD-L1 expression. 56 Ipilimumab has also been investigated in a phase II trial in mRCC; however, just 12% of patients achieved a partial response, with a substantial amount of toxicities. 57 ICIs are now being tested in combination with other ICIs and targeted agents. Dual immune checkpoint inhibition observed with the PD-1 inhibitor (nivolumab) and the CTLA-4 inhibitor (ipilimumab) has shown encouraging activity in clear cell RCC. Nivolumab and Ipilimumab target different compartments of the immune response, and, thus, are synergistic in their ability to induce the immune response. 58 Two different dosing cohorts (3 mg/kg nivolumab, 1 mg/kg ipilimumab [N3I1] and 1 mg/kg nivolumab, 3 mg/kg ipilimumab [N1I3]) have shown a remarkable activity, with 40% of patients experiencing durable responses in both arms. 59 However, the treatment arm with the lower dose of ipilimumab was better tolerated, with one-third of patients experiencing grade 3-4 treatment-related toxicity versus two-thirds of patients in the N1I3 arm. A large phase III trial (Checkmate 214) has accrued and pivoted this combination against sunitinib in a first-line setting. Results are expected, and could be practice changing. The ongoing clinical trials regarding ICIs for RCC are listed in Table 3 .
Tyrosine kinase inhibitors have the potential to augment an immune response by suppressing myeloid-derived suppressor cells and T regulatory cells, 1 which indicates that they might combine well with immunotherapy. 6, 60 A phase I trial of nivolumab and sunitinib had an impressive ORR of 52%; however, the treatment was associated with grades 3-4 adverse events in 73% of the patients. Two additional ongoing trials are investigating the combination of axitinib with avelumab in a first-line setting (NCT02493751), and axitinib with pembrolizumab in a second-line setting (NCT0213374). Treatment beyond progression of RCC is controversial. Anecdotal case reports, as well as data on pseudo-progression in immunotherapies, has raised questions about how to treat patients after progression. Two recent abstracts were presented on this topic and arrived at opposite conclusions. Escudier et al. stated that of 170 patients who were treated beyond progression, 14% had >30% tumor burden reduction, whereas the FDA reported that of 171 patients who were treated beyond PD, just 2.9% achieved a partial response. Of note, there is still an open question as to whether patients need to see a tumor burden reduction to achieve clinical benefit in this setting. As presented by McDermond during ASCO 2016, 19 patients showing PD as the best response were alive at 4-5 years of follow up. 42 Because there are many immunotherapies in development, it is crucial to select the right therapy for each patient. Currently, PD-L1 expression on the tumor cell has not been a very strong biomarker in RCC, especially given that differences in primary and metastatic tumors have been observed. 62 Additional biomarkers have been described in a study that required pretreatment and on-treatment biopsies along with serial blood collection; however, it is clear that there is no single biomarker that is related to response. 63 A total of 91 mRCC patients had tumor biopsies from metastatic sites before and after nivolumab therapy, and PD-L1 expression on tumors and TILs as well as gene expression analysis were investigated. Of 56 baseline biopsies, 32% had ≥5% PD-L1 expression, and there was no consistent change from baseline to on-treatment biopsies. Transcriptional changes in tumors on-treatment included upregulation of IFNc-stimulated genes (e.g. CXCL9). Median increases in chemokine levels from baseline to cycle 2 day 8 were 101% (CXCL9) and 37% (CXCL10) in peripheral blood. Increased T-cell infiltrate and increased cell-mediated immune transcripts have also been associated with response. There have also been multiple smaller attempts to associate pretreatment or nephrectomy samples with response to immunotherapy. RCC is not a hypermutated tumor, unlike other tumor types with strong responses to immunotherapy, which suggests that some factor in the metabolism, microenvironment or mutational landscape might be driving the response in this tumor type. 42 
Predictive biomarkers
Despite recent advances in ICIs, the real benefits are still limited to a minority of patients (often <20%) who probably have a pre-existing immune response that can be unconstrained by immune checkpoint inhibition. 64, 65 The establishment of predictive biomarkers for ICIs is, therefore, of utmost importance to maximize therapeutic benefit. One or more biomarker approaches that have high positive and negative predictive values are required to assist oncologists in treatment recommendations for patients. Multiple biomarker strategies have emerged that focus on identifying aspects of PD-L1 expression, T-cell inflamed phenotype and so-called tumor foreignness (e.g. mutational load, neoantigens) as approaches that are associated with clinical outcomes for ICIs.
Direct assessment of PD-L1 expression on tumor cells is a logical biomarker for the prediction of treatment response to anti-PD-1 or anti-PD-L1 therapies. However, patients whose disease is PD-L1-negative by immunohistochemistry can still achieve clinical benefit with anti-PD-1 or anti-PD-L1 therapies. The poor reliability of PD-L1 immunohistochemistry as a biomarker for anti-PD-1 or anti-PD-L1 therapies is probably the result of multiple variables. 66 First, PD-L1 expression is regulated by various mechanisms, including the MAPK and PI3K or Akt pathways; transcriptional factors HIF1, STAT3 and NFkB; and epigenetic factors. 67 PD-L1 expression can be transient, and intrapatient and even intratumor heterogeneity in PD-L1 tumor expression can exist. 68 Therefore, tumor sampling at one time-point or at only one tumor 69 Another important aspect is that PD-L1 immunohistochemistry alone does not consider factors that could impede the anti-PD-1 or anti-PD-L1 therapy response, such as whether active immune-cell engagement of the PD-1 or PD-L1 axis occurs in the tumor microenvironment or whether other concurrent suppressive immune pathways (e.g. IDO, FoxP3+ regulatory T cells and LAG3) are present. PD-L1 immunohistochemistry alone is not yet an adequate biomarker for routine clinical use in deciding which patients to offer anti-PD-1 or anti-PD-L1 therapy.
Preclinical studies have identified neoantigens produced by somatic mutations in passenger genes of tumor cells as primary drivers of antitumor adaptive immune responses. 70, 71 Rooney et al. showed that immune cytolytic activity, measured by intratumoral perfolin 1 and granzyme B gene expression (presumably produced by effector lymphocytes) is associated with higher mutational count, and they predicted antigenic neoepitopes in a range of solid tumor malignancies. 72 A phase II study of atezolizumab for locally advanced and metastatic urothelial carcinoma showed a higher mutational load by targeted exome sequencing in patients achieving CR or partial response than the load in patients with stable disease or progressive disease as their best response. 34 Strategies that combine two or more methods for capturing the immune status of the tumor microenvironment might be more effective as a composite predictive biomarker for ICIs. High tumor PD-L1 expression can be present even when TIL counts are low, and tumors with high TIL density might not express PD-L1. 73, 74 In both scenarios, the clinical activity of anti-PD-1 or anti-PD-L1 monotherapy might be low, but could be inaccurately predicted to be high if either PD-L1 status or TIL density alone were used as a biomarker. Similarly, not all high mutational or neoantigen burden tumors show sign of pre-existing immune activity, which is thought to be one of the prerequisites for immunotherapy approaches. 8, 72 Multiple concurrent immune-suppressive mechanisms can also be present in the tumor microenvironment, including CTLA-4, PD-L2, LAG3, IDO1 and interleukin-10, which are likely to become important targets for identification as novel combination therapy strategies become available.
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Conclusions
Immunotherapy is providing urological cancer patients with a variety of new therapeutic options. The approval of nivolumab and atezolizumab is only the beginning for treatment of urological malignancies with immunotherapy. These therapies have shown unprecedented responses in patients who would otherwise have limited options; however, only certain patients obtain this benefit. Consequently, investigation of predictive biomarkers, novel agents and improved combination strategies is required.
